Kito Capital: An IPO Allocation, a Free Trip and a Bonus Tied to the Quarter

1. The personal IPO allocation is an inducement, not a gift. 20,000 shares at 42 with a grey-market value of 59 is an expected gain of about KES 340,000 - and it is offered by a firm seeking commission business. Accepting it makes Amani's judgement about Safari, and about which clients get the stock, purchasable. This engages the duty to place client interest first and the prohibition on accepting benefits that could impair independence; it also breaches most firms' personal-account dealing rules, which require pre-clearance and often bar IPO allocations from a broker that does business with the firm.

2. The Cape Town trip is a soft-dollar inducement. KES 450,000 is 1.9% of the annual commission Safari earns. If it is not disclosed and approved, it is an undisclosed benefit flowing from order flow - the classic mechanism by which best execution quietly stops being about execution.

3. The allocation method is a conflict of interest made operational. Prioritising the five largest commission payers converts an investment opportunity into a rebate. IPO allocations are limited, valuable and must be allocated on objective, pre-disclosed criteria; allocating them as a reward transfers value from smaller clients to larger ones.

4. The bonus horizon explains the pressure. 20% of quarterly outperformance rewards a quick paper gain in a hot issue - precisely the incentive that turns allocation policy into a performance tool. Note the structure, do not just blame the individual.

Governing principle: the IPO is an asset like any other; allocations should be a function of client mandate and suitability, never of revenue or of the manager's own interest.

A defensible method:

1. Suitability filter first. Identify accounts whose mandates permit the sector, whose risk profile and liquidity needs fit an illiquid/new issue, and whose target weight for that exposure is not already satisfied. Exclude accounts with mandate restrictions - and document the exclusions.
2. Pre-committed allocation policy, written before the book closes. For example: pro-rata to the size of each eligible account's unmet target exposure, with a cap per client, and a minimum allocation size below which an allotment is not economically sensible.
3. No discretion in the room. The allocation should be run by operations/compliance on the policy, not chosen by the PM after seeing who is 'loyal'.
4. Scale-back applied pro rata and symmetrically. If the issue is eight times covered, everyone eligible gets the same fraction; no client jumps the queue.
5. Record and disclose: keep the allocation schedule, the eligibility list, the scale-back maths and the approvals; disclose the policy to clients.

On the personal allocation: decline it. Even disclosed and pre-cleared, taking stock in an issue the firm is simultaneously allocating to clients makes Amani's interest and his clients' interest the same trade, and he is on both sides of the allocation decision. The safe and defensible answer is to return the allocation and place the broker relationship on a documented, disclosed footing. If the firm permits personal IPO participation at all, it must be from an unrelated bookrunner, pre-cleared, and outside any issue the firm's clients are being allocated.

The trip: decline unless it is a genuine, substantive research event where attendance can be justified as a business expense paid by Kito itself. Paid-for travel from a broker whose commissions you control is an inducement and must be either refused or approved under a written gifts-and-entertainment policy with a monetary threshold far below KES 450,000, logged in a register, and disclosed.

The commission relationship:

1. Best execution standstill. Test whether Safari's execution is competitive on price, speed and quality; if it is not, the commission is being directed for relationship reasons and the clients are paying for it.
2. Separate research from execution. If research is being paid for through commissions, that is a soft-dollar arrangement requiring disclosure, a written budget and evidence the research benefits all clients, not just the PM.
3. Tender or review the panel. Rotate and benchmark at least annually; the 24m is client money, and concentration with one broker that behaves this way is a governance red flag.

Governance and disclosure:

• Escalate to compliance and the board (or its audit/conduct committee); document the decision and the reasoning, not just the outcome.
• Disclose the conflict to affected clients in plain terms: the broker relationship, any soft-dollar arrangements, and the IPO allocation policy.
• Recommend a conflicts-of-interest register entry and a fix to the bonus design: measure over rolling three years and include a conduct/risk adjustment so that a quick paper gain cannot be monetised in one quarter.
• Adopt a personal-account dealing code with pre-clearance and a blackout around any issue the firm is allocating to clients.
• Note the regulatory dimension: the conduct-of-business rules of the capital markets regulator cover inducements, fair treatment of clients and best execution, so the firm should assume this is examinable, not merely embarrassing.